-
ERK-IN-1
- names:
ERK-IN-1
- CAS号:
1715025-32-3
MDL Number: - MF(分子式): C26H27BrF3N5O2 MW(分子量): 578.42
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | |
| 英文别名 | ERK-IN-1 |
| CAS号 | 1715025-32-3 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C26H27BrF3N5O2 |
| 分子量 Molecular Weight | 578.42 |
| 溶解度Solubility | |
| 性状 | |
| 储藏条件 Storage conditions | 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description. |
| 产品说明 | |
| Introduction | ERK-IN-1 (compound B) is aRAFandERK1/2inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1]. |
| Application1 | |
| Application2 | |
| Application3 |
ERK-IN-1 (compound B) 为RAF和ERK1/2的抑制剂,通过激活MAPK通路中的突变来治疗增生性疾病。这种活性与KRAS-突变型非小细胞肺癌、BRAF-突变型非小细胞肺癌、KRAS-突变型胰腺癌、KRAS-突变型结肠癌以及KRAS-突变型卵巢癌尤为相关。ERK-IN-1 (compound B) is aRAFandERK1/2inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].
| 【1】.WO2018051306A1. |
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


